CIDARA THERAPEUT.DL-,0001 WKN: A14R2R ISIN: US1717571079 Forum: Aktien Thema: Hauptdiskussion

- 1,40 % SuperDuperDump

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced data from three posters at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, which takes place virtually Feb. 17-19, 2021. The presentations highlight new clinical and preclinical data on rezafungin, Cidara’s novel, once-weekly echinocandin in Phase 3 development for the treatment and prevention of serious fungal infections. "We are delighted to present data describing the recent highlights from our antifungal program,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We are gathering critical insights into potential patient outcomes through exploratory analyses of the completed Phase 2 STRIVE trial of our novel long-acting echinocandin, rezafungin, for the treatment of candidemia and/or invasive candidiasis. We believe rezafungin has the potential to improve outcomes, particularly in high-risk populations, including immunocompromised and critically ill patients with severe comorbidities.” Three poster presentations report new findings on rezafungin for the treatment and prevention of severe fungal infections. Taylor Sandison, M.D., M.P.H., chief medical officer of Cidara, will also be delivering an oral overview of long-acting rezafungin. Highlights from the published abstracts are as follows: Analysis of outcomes from the completed Phase 2 STRIVE trial of rezafungin for the treatment of candidemia and/or invasive candidiasis based on immunocompromised status demonstrated rezafungin was safe and efficacious in a high-risk, immunocompromised patient population; the overall response rate, investigator-assessed clinical cure and mycological response at Day 14 was 75% (9/12) in high-risk immunocompromised patients treated with rezafungin compared to 66.7% (6/9) in those treated with standard of care (caspofungin). Additional evaluation of patient outcomes from the STRIVE trial based on renal function demonstrated that the safety and efficacy of rezafungin were not adversely affected by renal impairment, a common comorbidity in critically ill patients with invasive fungal infections. Administration of long-term (up to eight weeks of) rezafungin initiated six weeks post-infection with P. murina resulted in robust eradication of Pneumocystis in the lungs in immunosuppressed mice. Presentation details will be accessible on the Publications section of the Cidara website at the conclusion of the conference.

Von 20 eins 100%? Hä was😂 Is klar

Interessant wird es erst nach Überwindung von 2,70

Naja er postet viel am Tag.... wenn von 20 mal eins 100% erreicht ist er gleich ein Stockpusher?

SuperDuperInvestor

Danke

Wie heist der Stockpusher?

Oder global Battery kurzzeitig über 1000%

Bionano hat er z.B letztes Jahr gepostet ist von 0,4 auf 12,50€

Die 10€ hier sind locker drin

Morgen 17:30 wird eventuell die Hölle los sein. Alles was er gepostet hat ist in einem Monat mindestens 300% hoch manche Sachen bis auf 4000%

Einfach mal Twitter schauen 👀

Wer ist das denn? :D

SuperDuper der bekannteste Stock Pusher nach wallstreetbets hat das hier empfohlen. Bald gehts ab.